Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Otto C Boerman

Showing results (281-290 of 319) with videos related to

Pageof 32
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2011
Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptidesPeter Laverman, Lieke Joosten, Annemarie Eek, et al.
European Urology|September 18, 2012
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinomaAlexander B Stillebroer, Otto C Boerman, Ingrid M E Desar, et al.
Molecular Pharmaceutics|October 9, 2014
Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expressionSandra Heskamp, Otto C Boerman, Janneke D M Molkenboer-Kuenen, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PETIris Verel, Gerard W M Visser, Otto C Boerman, et al.
Theranostics|May 11, 2016
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic AgentKristell L S Chatalic, Sandra Heskamp, Mark Konijnenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 22, 2014
Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancerKristell L S Chatalic, Gerben M Franssen, Wytske M van Weerden, et al.
EJNMMI Physics|October 27, 2015
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapyWietske Woliner-van der Weg, Rafke Schoffelen, Robert F Hobbs, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 20, 2014
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancerRafke Schoffelen, Wietske Woliner-van der Weg, Eric P Visser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic responseAdrienne H Brouwers, Wilhelmina C A M Buijs, Peter F A Mulders, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone MarrowLaurens T van der Meer, Samantha Y A Terry, Dorette S van Ingen Schenau, et al.
Pageof 32

Showing results (281-290 of 319) with videos related to

Sort By:
Pageof 32
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2011
Comparative biodistribution of 12 ¹¹¹In-labelled gastrin/CCK2 receptor-targeting peptidesPeter Laverman, Lieke Joosten, Annemarie Eek, et al.
European Urology|September 18, 2012
Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinomaAlexander B Stillebroer, Otto C Boerman, Ingrid M E Desar, et al.
Molecular Pharmaceutics|October 9, 2014
Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expressionSandra Heskamp, Otto C Boerman, Janneke D M Molkenboer-Kuenen, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with PETIris Verel, Gerard W M Visser, Otto C Boerman, et al.
Theranostics|May 11, 2016
Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic AgentKristell L S Chatalic, Sandra Heskamp, Mark Konijnenberg, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 22, 2014
Preclinical comparison of Al18F- and 68Ga-labeled gastrin-releasing peptide receptor antagonists for PET imaging of prostate cancerKristell L S Chatalic, Gerben M Franssen, Wytske M van Weerden, et al.
EJNMMI Physics|October 27, 2015
Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapyWietske Woliner-van der Weg, Rafke Schoffelen, Robert F Hobbs, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 20, 2014
Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancerRafke Schoffelen, Wietske Woliner-van der Weg, Eric P Visser, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2005
Radioimmunotherapy with [131I]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic responseAdrienne H Brouwers, Wilhelmina C A M Buijs, Peter F A Mulders, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 6, 2016
In Vivo Imaging of Antileukemic Drug Asparaginase Reveals a Rapid Macrophage-Mediated Clearance from the Bone MarrowLaurens T van der Meer, Samantha Y A Terry, Dorette S van Ingen Schenau, et al.
Pageof 32